Taking stock of the frenzied push into autoimmune disease

This is the online edition of Adam’s Biotech Scorecard, a new subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered every Thursday to their inbox.

Good morning! This is a magical time of the year in Boston, with trees in full bloom. I want to hear from you! Send me email at BiotechScorecard@statnews.com.

Where art thou, lupus patients?

This week, Cullinan Oncology, now known as Cullinan Therapeutics, became the latest company to pivot from cancer to autoimmune disease. It joins Crispr Therapeutics, Cabaletta Bio, Nkarta, Caribou Biosciences, Allogene Therapeutics, Gracell (AstraZeneca), Bristol Myers Squibb, Fate Therapeutics, Eliem Therapeutics/Tenet Medicines, and Century Therapeutics/Clade Therapeutics in making the same shift, either partially or completely.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In